HARVONI (ledipasvir/sofosbuvir)
HEPATITIS C NUCLEOS(T)IDE ANALOG NS5B POLYMERASE INHIBITORS · CHRONIC HEPATITIS C - GENOTYPE 1 ·+3
GILEAD SCIENCES
Drug class
Hepatitis C - NS5A Replication Complex Inhibitors
Hepatitis C nonstructural protein 5A (NS5A) replication complex inhibitors are a class of direct-acting antiviral medications. Read more about Hepatitis C - NS5A Replication Complex Inhibitors
6 drugs in this class 3 manufacturers
Drugs in Hepatitis C - NS5A Replication Complex Inhibitors
EPCLUSA (sofosbuvir/velpatasvir)
HEPATITIS C NUCLEOS(T)IDE ANALOG NS5B POLYMERASE INHIBITORS · CHRONIC HEPATITIS C - GENOTYPE 1 ·+5
GILEAD SCIENCES
VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)
HEPATITIS C VIRUS NS3/4A SERINE PROTEASE INHIBITORS · CHRONIC HEPATITIS C - GENOTYPE 1 ·+5
GILEAD SCIENCES
MAVYRET (glecaprevir/pibrentasvir)
HEPATITIS C VIRUS NS3/4A SERINE PROTEASE INHIBITORS · ACUTE HEPATITIS C ·+6
ABBOTT
LEDIPASVIR-SOFOSBUVIR (ledipasvir/sofosbuvir)
HEPATITIS C NUCLEOS(T)IDE ANALOG NS5B POLYMERASE INHIBITORS · CHRONIC HEPATITIS C - GENOTYPE 1 ·+3
ASEGUA THERAPEU
SOFOSBUVIR-VELPATASVIR (sofosbuvir/velpatasvir)
HEPATITIS C NUCLEOS(T)IDE ANALOG NS5B POLYMERASE INHIBITORS · CHRONIC HEPATITIS C - GENOTYPE 1 ·+5
ASEGUA THERAPEU
Filter & compare in the drug finder →
Opens the drug finder with Hepatitis C - NS5A Replication Complex Inhibitors preselected. Add indication or manufacturer filters there.
Hepatitis C nonstructural protein 5A (NS5A) replication complex inhibitors are a class of direct-acting antiviral medications.
They target and bind to the viral NS5A protein, a multifunctional phosphoprotein that is essential for the assembly and function of the hepatitis C virus replication complex.
By disrupting NS5A, these agents block both viral RNA genome replication and virion assembly.
They are indicated for the treatment of chronic hepatitis C virus infection across multiple genotypes, administered as standalone agents or, more commonly, within fixed-dose combination direct-acting antiviral regimens to achieve sustained virologic response.
-
nih.gov
Hepatitis C nonstructural protein 5A (NS5A) replication complex inhibitors are a class of direct-acting antiviral medications They target and bind to the viral NS5A protein, a multifunctional phosphoprotein that is essential for the assembly and function of the hepatitis C virus replication complex By disrupting NS5A, these agents block both viral RNA genome replication and virion assembly
-
nih.gov
Hepatitis C nonstructural protein 5A (NS5A) replication complex inhibitors are a class of direct-acting antiviral medications
-
nih.gov
They target and bind to the viral NS5A protein, a multifunctional phosphoprotein that is essential for the assembly and function of the hepatitis C virus replication complex
-
nih.gov
By disrupting NS5A, these agents block both viral RNA genome replication and virion assembly
-
fda.gov
They are indicated for the treatment of chronic hepatitis C virus infection across multiple genotypes, administered as standalone agents or, more commonly, within fixed-dose combination direct-acting antiviral regimens to achieve sustained virologic response
-
fda.gov
They are indicated for the treatment of chronic hepatitis C virus infection across multiple genotypes, administered as standalone agents or, more commonly, within fixed-dose combination direct-acting antiviral regimens to achieve sustained virologic response
-
fda.gov
They are indicated for the treatment of chronic hepatitis C virus infection across multiple genotypes, administered as standalone agents or, more commonly, within fixed-dose combination direct-acting antiviral regimens to achieve sustained virologic response
-
michigan.gov
They are indicated for the treatment of chronic hepatitis C virus infection across multiple genotypes, administered as standalone agents or, more commonly, within fixed-dose combination direct-acting antiviral regimens to achieve sustained virologic response
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.